Westfield Capital Management Co. LP Sells 94,073 Shares of Lantheus Holdings, Inc. $LNTH

Westfield Capital Management Co. LP lowered its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 5.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,495,072 shares of the medical equipment provider’s stock after selling 94,073 shares during the quarter. Westfield Capital Management Co. LP’s holdings in Lantheus were worth $122,387,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in LNTH. Harbor Capital Advisors Inc. grew its stake in shares of Lantheus by 24.7% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 190,008 shares of the medical equipment provider’s stock worth $15,554,000 after acquiring an additional 37,691 shares in the last quarter. Reinhart Partners LLC. lifted its position in shares of Lantheus by 16.4% in the second quarter. Reinhart Partners LLC. now owns 1,403,659 shares of the medical equipment provider’s stock worth $114,905,000 after purchasing an additional 197,719 shares in the last quarter. Swedbank AB boosted its holdings in Lantheus by 11.0% during the first quarter. Swedbank AB now owns 1,228,743 shares of the medical equipment provider’s stock worth $119,925,000 after purchasing an additional 121,500 shares during the last quarter. Strs Ohio bought a new position in Lantheus in the first quarter valued at $4,529,000. Finally, Select Equity Group L.P. increased its stake in Lantheus by 899.2% in the 1st quarter. Select Equity Group L.P. now owns 100,843 shares of the medical equipment provider’s stock valued at $9,842,000 after buying an additional 90,751 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Down 1.3%

Lantheus stock opened at $52.79 on Thursday. The company’s 50-day moving average price is $53.85 and its two-hundred day moving average price is $65.64. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49. The stock has a market cap of $3.50 billion, a P/E ratio of 14.04 and a beta of 0.04. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $111.29.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter. The business had revenue of $92.51 million during the quarter. Lantheus had a return on equity of 34.06% and a net margin of 17.82%. As a group, analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Truist Financial reaffirmed a “hold” rating and issued a $61.00 target price (down previously from $63.00) on shares of Lantheus in a research report on Monday, November 10th. B. Riley dropped their price objective on Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a research note on Tuesday, September 16th. JMP Securities decreased their target price on shares of Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a research note on Thursday, August 7th. Weiss Ratings lowered shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Saturday, October 25th. Finally, Mizuho decreased their price objective on shares of Lantheus from $120.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, August 7th. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $74.17.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.